Claims for Patent: 8,211,418

Summary for Patent: 8,211,418

Title:	Protein-based polymer tissue adhesives for medical use
Abstract:	Tissue adhesives formed by crosslinking albumin and/or gelatin with certain polyamines and/or polycarboxylates using a water-soluble carbodiimide are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug delivery; anti-adhesive applications; and as a bulking agent to treat urinary incontinence are described.
Inventor(s):	Chenault; Henry Keith (Hockessin, DE)
Assignee:	Actamax Surgerical Materials, LLC (Berkeley, CA)
Application Number:	12/904,230
Patent Claims:	1. A cured composition obtained from an aqueous mixture comprising: (a) at least one of albumin or gelatin; (b) a water-soluble carbodiimide; and (c) at least one water-dispersible multi-arm polyether amine, the total water-dispersible multi-arm polyether amine concentration being in the range of about 0.4% to about 20% by weight; and, (d) optionally, at least one polycarboxylate selected from the group consisting of carboxymethyl cellulose, carboxymethyl dextran, and carboxymethyl starch; wherein the aqueous mixture is allowed to cure; provided that: (i) if the aqueous mixture comprises albumin, but not gelatin, then the concentration of albumin in the aqueous mixture is about 20% to about 36% by weight; (ii) if the aqueous mixture comprises gelatin, but not albumin, then the concentration of gelatin in the aqueous mixture is about 12% to about 32% by weight; (iii) if the aqueous mixture comprises a mixture of albumin and gelatin, then the total concentration of albumin and gelatin combined is about 12% to about 36% by weight; (iv) the concentration of the water-soluble carbodiimide in the aqueous mixture is about 1% to about 10% by weight; (v) if the aqueous mixture comprises the polyether amine, but not the polycarboxylate, then the concentration of the polyether amine in the aqueous mixture is about 0.4% to about 20% by weight; (vi) if the aqueous mixture comprises both the polyether amine and the polycarboxylate, then the concentration of the polyether amine in the aqueous mixture is about 0.4% to about 20% by weight and the concentration of the polycarboxylate is about 0.4% to about 5% by weight. 2. The composition according to claim 1 wherein the albumin is selected from the group consisting of a mammalian serum albumin, an egg albumin, and mixtures thereof. 3. The composition according to claim 2 wherein the mammalian serum albumin is selected from the group consisting of bovine serum albumin, ovine serum albumin, porcine serum albumin, human serum albumin, equine serum albumin, lapine serum albumin, rat serum albumin, murine serum albumin, and mixtures thereof. 4. The composition according to claim 2 wherein the egg albumin is chicken egg albumin. 5. The composition according to claim 1 wherein said at least one albumin or gelatin, said water-soluble carbodiimide, said at least one polyamine, and said at least one polycarboxylate are sterilized. 6. The composition according to claim 1 wherein the aqueous mixture further comprises an additive selected from the group consisting of pH modifiers, viscosity modifiers, antimicrobials, colorants, healing promoters, surfactants, anti-inflammatory agents, thrombogenic agents, and radio-opaque compounds. 7. The composition according to claim 1 wherein the water-soluble carbodiimide is selected from the group consisting of compounds represented by structures 1 and 2, ##STR00002## wherein R.sup.1=hydrogen, methyl or ethyl, R.sup.2=methyl, ethyl, propyl, isopropyl or cyclohexyl, n=0, 1 or 2, m=1, 2 or 3, and X.sup.-=chloride, bromide, iodide, acetate, sulfate, hydrogen sulfate, methyl sulfate, methanesulfonate, ethanesulfonate, 1-propanesulfonate, 2-propanesulfonate, 1-butanesulfonate, benzenesulfonate, p-toluenesulfonate, or perchlorate. 8. The composition according to claim 1 wherein the water soluble carbodiimide is selected from the group consisting of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide methiodide, and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate. 9. The composition according to claim 1 wherein the water dispersible multi-arm polyether amine is selected from the group consisting of amino-terminated star polyethylene oxides, amino-terminated dendritic polyethylene oxides, amino-terminated comb polyethylene oxides, amino-terminated star polypropylene oxides, amino-terminated dendritic polypropylene oxides, amino-terminated comb polypropylene oxides, amino-terminated star copolymers of ethylene oxide and propylene oxide, amino-terminated dendritic copolymers of ethylene oxide and propylene oxide, amino-terminated comb copolymers of ethylene oxide and propylene oxide, amino-terminated star copolymers of ethylene oxide and trimethylene oxide, amino-terminated dendritic copolymers of ethylene oxide and trimethylene oxide, amino-terminated comb copolymers of ethylene oxide and trimethylene oxide, amino-terminated star copolymers of ethylene oxide and butylene oxide, amino-terminated dendritic copolymers of ethylene oxide and butylene oxide, amino-terminated comb copolymers of ethylene oxide and butylene oxide, amino-terminated star copolymers of ethylene oxide and tetrahydrofuran, amino-terminated dendritic copolymers of ethylene oxide and tetrahydrofuran, amino-terminated comb copolymers of ethylene oxide and tetrahydrofuran, amino-terminated dendritic polyamidoamines, polyoxyalkylene triamines, and mixtures thereof. 10. The composition according to claim 1 wherein the weight-average molecular weight of the water-dispersible multi-arm polyether amine is between about 2,000 and about 100,000 Daltons. 11. The composition according to claim 1 wherein the water-dispersible multi-arm polyether amine is an eight arm poly(ethylene glycol) having a molecular weight of 10,000 Daltons.

Details for Patent 8,211,418

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2024-12-01
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2024-12-01
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2024-12-01
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2024-12-01
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2024-12-01
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2024-12-01